General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Gilead Q1 Earnings Preview: Most Gains Wiped Out- Seeking Alpha | news.google.com • |
Gilead Q1 Earnings Preview: Most Gains Wiped Out- Seeking Alpha | news.google.com • |
Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics | news.google.com • |
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect? | zacks.com • |
Illinois Municipal Retirement Fund Sells 79,102 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | news.google.com • |
Undervalued Icons: 3 Household Names Trading at Steep Discounts | investorplace.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-25 | 2024-03 | 0.71 | N/A | N/A | N/A |
2024-02-06 | 2023-12 | 1.76 | 1.72 | -0.04 | -2.27% |
2023-11-07 | 2023-09 | 1.91 | 2.29 | 0.38 | 19.90% |
2023-08-03 | 2023-06 | 1.6 | 1.34 | -0.26 | -16.25% |
2023-04-27 | 2023-03 | 1.63 | 1.37 | -0.26 | -15.95% |
2023-02-02 | 2022-12 | 1.5 | 1.67 | 0.17 | 11.33% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | B of A Securities | Upgrade | Neutral | Buy |
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-09-05 | HSBC | Upgrade | Reduce | |
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-08-08 | Benchmark | Upgrade | Buy | Buy |
2023-08-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-05-02 | BARTON JACQUELINE K | Director | 22.23K | Stock Award(Grant) |
2024-03-07 | DICKINSON ANDREW D | Chief Financial Officer | 134.98K | Conversion of Exercise of derivative security |
2023-05-02 | LOFTON KEVIN E | Director | 0.00 | Stock Award(Grant) |
2024-02-01 | LOVE TED WENDELL | Director | 512.00 | Stock Award(Grant) |
2024-03-07 | MERCIER JOHANNA | Officer | 118.43K | Conversion of Exercise of derivative security |
2024-03-07 | O'DAY DANIEL PATRICK | Chief Executive Officer | 484.85K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 126.19M | 9.73B | 10.13% |
2023-06-29 | Vanguard Group Inc | 113.37M | 8.74B | 9.10% |
2023-06-29 | Capital World Investors | 80.93M | 6.24B | 6.50% |
2023-06-29 | State Street Corporation | 59.32M | 4.57B | 4.76% |
2023-06-29 | Capital Research Global Investors | 57.90M | 4.46B | 4.65% |
2023-06-29 | Dodge & Cox Inc | 33.98M | 2.62B | 2.73% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 38.97M | 3.00B | 3.13% |
2023-09-29 | Income Fund of America Inc | 34.44M | 2.58B | 2.76% |
2023-06-29 | Vanguard 500 Index Fund | 29.70M | 2.29B | 2.38% |
2023-06-29 | Dodge & Cox Stock Fund | 24.24M | 1.87B | 1.95% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 21.14M | 1.62B | 1.70% |
2023-09-29 | Washington Mutual Investors Fund | 20.14M | 1.51B | 1.62% |
Dividend | Date |
---|---|
0.77 | 2024-03-14 |
0.75 | 2023-12-14 |
0.75 | 2023-09-15 |
0.75 | 2023-09-14 |
0.75 | 2023-06-14 |
0.75 | 2023-03-14 |
Split | Date |
---|---|
2 : 1 | 2013-01-28 |
2 : 1 | 2007-06-25 |
2 : 1 | 2004-09-07 |
2 : 1 | 2002-03-08 |
2 : 1 | 2001-02-22 |
Entrepreneurship isn't easy, just like protesting you don't have clue of what's going on. That's why I encourage people to passively do something spectacular incase you're seeing for an option on how to make money online, get in touch with Georgia J Imogen
All thanks to Mrs. Karen J Adams that helped me achieve my dreams through her trading program, I made over $30,000 in duration of 4 days she's so excellent and amazing. Visit her on TELEGRAM ᏦᎪᎡᎬΝ Ꭻ ᎪᎠᎪᎷՏ or WhatsApp +❶❽❶❷❷❼⓿❻❽⓿❼
NFA Guys!!!! LOOK into ATER !!! Look at the facts, Numbers are lined up & we own float SI is above 40% , 100% utilization for 72 days, we own the float, CTB is high, we just need volume, SQUEEZE bound to happen Join ATER discord n let us know ur new.HODL!! SQUEEZE PLAY!!! Just need volume!! Lookup AnonFtheHF vids on youtube or
DO YOUR OWN DD IF YOU DONT BELIVE, SEE FOR YOURSELF!!!!
Just a BULL sticking it to SHORTS/HF. Love ya’ll!!!Peace out brothers!! Ticker: ATER
NFA
$GILD Fantastic Earnings! Very Bullish here
$GILD Undervalued big time!
$GILD Tremendously Good numbers!!!!
$GILD BLOW OUT EARNINGS!!!
$GILD Solid move up. More to come
$CRBU
Take a look at Caribou Biosciences. $CRBU
Leader in CRISPR Gene editing. Cure to all diseases.
Founded by Nobel winner Jennifer Doudna and CEO Rachel Haurwitz.
Market cap 1.5 Billion.
They have 14,453,932 shares of Intellia (NTLA). Worth $2.5 Billion alone. Check out filings:
https://www.sec.gov/edgar/browse/?CIK=1619856&owner=exclude
They have about $500 Million in cash from recent IPO.
Listen to The Code Breaker by Walter Isaacson on Audible. https://www.audible.com/pd?asin=179711705X&source_code=ASSORAP0511160006
Check out patents:
Working on cure for cancer.
This has potential for x 1000
New CRISPR/Cas9 patent issued to Carribou Bio recently
Do your own due diligence.
Good luck
$GILD Gilead Sciences (GILD) Remains Undervalued Despite Outperformance - Oppenheimer
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $100.00 price target on Gilead Sciences (NASDAQ: GILD) noting that late 2020, the company has steadily been delivering positive pipeline updates (Yescarta in 2nd-line LBCL), while prepping investors for a raft of approaching clinical/regulatory catalysts. Despite this, the analyst detects 'categorical negative sentiment' often expressed by investors.
The analyst stated "We believe that starting with Yescarta's recent 2nd-line success (possibly adding margin ≥2022), the domino effect for GILD's oncology and virology pipeline could be in play. With remdesivir potentially having a long revenue tail against COVID-19 (also GILD developing orals) and fundamentals improving, we believe investors should pay heed."
$GILD Gilead Sciences wins reversal of $1.2 billion award in patent case with Bristol Myers
$GILD Gilead Sciences (NASDAQ:GILD) Earns Buy Rating from Royal Bank of Canada
Gilead Sciences logoGilead Sciences (NASDAQ:GILD)'s stock had its "buy" rating restated by stock analysts at Royal Bank of Canada in a research report issued to clients and investors on Monday, TipRanks reports. They currently have a C$84.00 target price on the biopharmaceutical company's stock.